My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
February 2014
Top Stories
Antimicrobial Resistance Efforts Continue on Capitol Hill
Antimicrobial resistance continues to gain momentum with the introduction of the Antibiotic Development to Advance Patient Treatment (ADAPT) Act  in the House of Representatives and President Obama’s mention of the issue in his State of the Union Address last month. IDSA continues to advocate for support of the bill on Capitol Hill, to urge lawmakers to consider important additions to the proposed legislation, and to urge President Obama (PDF) to fulfill his State of the Union Address promise.

As reported in last month’s issue of IDSA News, the ADAPT Act would advance drug development by establishing a new, limited-population antibacterial and antifungal approval pathway for drugs to treat serious or life-threatening infections where there exists an unmet medical need.  IDSA first put forward this concept in 2012, and the ADAPT Act is a result of IDSA’s persistent advocacy on this issue.

IDSA worked closely with Reps. Gene Green (D-TX) and Phil Gingrey (R-GA), who is a physician, to develop this legislation, which is an important successor to the GAIN Act, introduced by Reps. Gingrey and Green, supported by IDSA, and signed into law in 2012.

In a joint letter (PDF) to Reps. Gingrey and Green, IDSA, along with several public health and patient organizations, applauded the bill and recommended strengthening a provision in the bill regarding labeling of drugs approved under this pathway. The groups urged lawmakers to require the label to include a prominently placed visual element, such as a logo, to clearly indicate to the healthcare community that these drugs are approved for a limited population and must be used properly.

You can urge Congress to pass ADAPT by visiting IDSA’s Take Action web page, which includes an action alert that makes it easy to email your congressional representatives and urge them to co-sponsor and strengthen the Act.

In addition to efforts on Capitol Hill, the National Institute for Allergy and Infectious Diseases (NIAID) released a new report, NIAID’s Antibacterial Resistance Program: Current Status and Future Directions (PDF), which NIAID regards as an update of its 2008 research agenda published in The Journal of Infectious Diseases.  The report includes an update on the Antibacterial Resistance Leadership Group (ARLG), which is co-led by IDSA’s Antimicrobial Resistance Committee chair Henry F. “Chip” Chambers, MD, FIDSA.




< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
Revised Standards for Adult Immunization Now Available
Fecal Microbiota Transplantation Resources Now Available from IDSA
Clinical Practice Management
Ryan White and Health Insurance Interface: One Clinic's Approach
Policy and Advocacy
Support IDSA Efforts to Advocate for SGR Repeal
HIVMA Urges Insurers to Offer Comprehensive, Quality Coverage
Education and Resources
OFID Establishes Special Peer Review Track for Fellows of IDSA
IDSA Launches New Catalog of Clinical Care Fellowships Abroad
Internal Medicine Subspecialty Milestones Now Online
You and Your Colleagues
In Memoriam: Robert Moellering, Jr., MD, FIDSA (1936-2014)
Call for Nominations for 2014 Society Awards
New Members
Top Stories
President's Message: Volunteering with IDSA Can Take Many Forms
Antimicrobial Resistance Efforts Continue on Capitol Hill
IDWeek 2014 Registration to Open Soon
Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.